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Abstract  
Probiotics and prebiotics are microbiota management tools for improved host health. 
They target gastrointestinal effects via the gut, although direct application to other 
sites such as the oral cavity, vaginal tract and skin are being explored. Here, we 
describe gut-derived effects in humans. In the past decade, research on the gut 
microbiome has rapidly accumulated, accompanied by increased interest in 
probiotics and prebiotics as a means to modulate the gut microbiota. Given the 
importance of these approaches for public health, it is timely to reiterate factual and 
supporting information on their clinical application and use. In this Review, we 
discuss scientific evidence on probiotics and prebiotics, including mechanistic 
insights into health effects. Strains of Lactobacillus, Bifidobacterium, and 
Saccharomyces have a long history of safe and effective use as probiotics, but 
Roseburia spp., Akkermansia spp., Propionibacterium spp. and Faecalibacterium 
spp. show promise. For prebiotics, glucans and fructans are well proven with 
evidence building on prebiotic effects of other substances (e.g. oligomers of 
mannose, glucose, xylose, pectin, starches, human milk; and polyphenols).  
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Key Points 
 The human gut microbiota is integral to health and is associated with a variety 
of diseases  
 Therapeutic and prophylactic effects of some probiotics and prebiotics for a 
variety of gut-related disorders might be, at least in part, mediated through 
modification of the microbiota and/or its function 
 Probiotic microorganisms act via a variety of means, including modulation of 
immune function, production of organic acids and antimicrobial compounds, 
interaction with resident microbiota, interfacing with the host, improving gut 
barrier integrity and enzyme formation  
 Prebiotics are substrates that are selectively utilized by host microorganisms 
conferring a health benefit; prebiotic effects include defence against 
pathogens, immune modulation, mineral absorption, bowel function, 
metabolic effects and satiety  
 Use of some probiotics and prebiotics is justified by robust assessments of 
efficacy, but not all products have been validated; the goal is evidence-based 
use by healthcare professionals  
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[H1] Introduction  
When the Argentinian government requested of the Food and Agriculture 
Organization of the United Nations that an expert panel be formed to evaluate the 
health and nutritional properties of probiotics in food in 2000, it precipitated the re-
emergence of a concept long part of human history. International recognition of the 
concept of probiotics, and coalescence around a definition of probiotic offered by this 
expert consultation,1 established an important consensus foundation. 
The definition of probiotic decided by the consultation retained the essence of 
historical definitions offered over previous decades. It was intentionally broad, to 
encompass a wide variety of microorganisms, hosts, benefits, target sites and 
product types. It has stood the test of time and was reaffirmed, but grammatically 
corrected, in 2014 to the consensus definition of probiotics, which is: “live 
microorganisms that, when administered in adequate amounts, confer a health 
benefit on the host”.2 
Studies abound that describe how microbes are integrated into life processes 
and define ways that beneficial microorganisms—both commensal and externally 
applied—affect physiological homeostasis and host function.3 On the horizon is the 
promise of newly constructed recombinant strains and promising novel microbial 
species, which await testing in vivo. However, as these advances develop, we should 
recognize actionable evidence that is currently available. As will be discussed, 
convincing evidence exists for some established probiotics, which should be 
incorporated into health management. This incorporation includes complementary 
use with pharmaceutical agents, foods and lifestyle. Education of consumers, 
practitioners and regulators will facilitate appropriate use and point out needs for 
further research, which will hopefully include exploration of how to reach the 
individuals at greatest need with affordable and reliable probiotic products.4 
Prebiotics, first defined in 19955, have been used to manipulate microbes in 
the host to improve measurable health outcomes. An update to the prebiotic 
definition published in 2017 as “a substrate that is selectively utilized by host 
microorganisms conferring a health benefit” was compelled by the need to clarify 
what did and did not constitute a prebiotic substance in the face of scientific 
advances.6 The desire to optimize, for improved health, the microbial world 
associated with us has led to the development of compounds targeting an ever-
expanding group of microorganisms and benefits that are derived through them. No 
longer are prebiotics seen simply as boosters of the growth of bifidobacteria and 
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lactobacilli, with recognition of their effects on system-wide metabolic and 
physiological readouts.6 Although the intestine remains the gateway to most of these 
effects, it is not an exclusive one. The extent to which prebiotics can affect microbial 
communities of the urogenital tract, oral-nasal areas and skin is now the subject of 
intensive exploration.7  
This Review describes the current understanding of probiotic and prebiotic 
mechanisms of action, provides important examples of clinical studies on probiotic 
and prebiotic applications, and discusses current knowledge on mechanisms at the 
heart of these effects.  
 
[H1] Human gut microbiome  
The human gut is predominantly inoculated at birth. Microbial diversity develops as 
feeding and dietary patterns mature. It resembles the ‘adult-like’ microbiota after 3-5 
years.8 Because of variations in pH, substrate concentration, Eh (redox potential, 
activity of electrons) and transit time, microbial numbers vary between different 
anatomical regions of the gut.9 The stomach harbours fewer microbes than the small 
and large intestines.10 Studies using metagenomic approaches have highlighted the 
complex inter-relationship between our resident intestinal microbiota and mammalian 
metabolism.11 Through the process of fermentation, anaerobic gut bacteria 
metabolise substrates to form end products such as organic acids and gases.12 The 
main precursors for fermentations are dietary carbohydrates, proteins and lipids, as 
well as indigenous secretions such as mucin. This anaerobic metabolism contributes 
positively towards host daily energy requirements and homeostasis in the gut.13 
Ideally, the human host lives in harmony with its complex gut microbiota in a state 
that promotes physiological resilience.14 However, dysbiosis can result from 
challenges such as medications, infections, ageing, lifestyle, surgery and poor 
nutrition,14,15 
In humans, a range of acute and chronic disorders can be a consequence of 
perturbation of gut microbial communities.16-18 On a chronic basis, inflammatory 
bowel disease (IBD), obesity and irritable bowel syndrome (IBS) have all been linked 
to intestinal bacteria and their activities.10 This aspect opens up the possibility of 
influencing the microbiota to reduce disease risk, fortify homeostasis and, in some 
cases, improve therapeutic status. Diet is a principal driver of gut fermentation and 
therefore can greatly influence functionality of the indigenous microbiota.19 Prebiotics 
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are popular dietary approaches for modifying the gut microbiota to improve host 
health,6 as they are affordable, effective, safe and accessible.  
 
[H1] Probiotics 
As the concept of probiotics evolved over the past decades, the assumption was that 
their effects would be mediated through direct interaction with commensal 
microbiota. Some early definitions stipulated that probiotics functioned “by 
contributing to (the host’s) intestinal microbial balance”20 or “by improving the 
properties of the indigenous microflora”.21 However, the current consensus definition 
of probiotics does not stipulate that probiotic effects are only microbiota-mediated, 
and indeed, other types of mechanisms are known. This idea that probiotics function 
in ways that might act beyond affecting the colonizing microbiota opens the door to a 
wider range of probiotic possibilities, encouraging innovation in the field.  
Much of our knowledge on probiotic mechanisms is based on research using 
in vitro, animal, cell culture or ex vivo human models. Figure 1 compiles known 
mechanisms distributed among various probiotic strains. Not all mechanisms have 
been confirmed in humans nor do they exist in every probiotic strain. Although 
multiple mechanisms likely co-express in a single probiotic, the importance of any 
given mechanism will depend on many factors. For example, in an inflamed intestine, 
the ability to down-regulate inflammatory mediators and increase epithelial barrier 
function may be most important,22,23 whereas the ability to increase short chain fatty 
acids and hydration in the colon may be more important to normalizing intestinal 
motility.24   
Research elucidating mechanisms of probiotics often relies on in vitro or 
animal studies. Probiotics are not unique in this regard. Animal studies have not 
always translated to humans;25 notable examples are probiotics for Crohn’s disease 
and mental health function.26,27  Furthermore, inherent difference among probiotic 
strains exists, for example in the findings that one probiotic (in this case in 
conjunction with a prebiotic) significantly prevented sepsis in infants,28 whereas a 
different formulation failed to prevent necrotizing enterocolitis.29   
The historic concept of ‘colonization resistance,’30 the situation whereby 
native gut microbiota occupy host tissues to exclude infection by potential pathogens 
(resident or invading), is another mechanism attributed to probiotics.31 Expression of 
colonization resistance is likely a sum outcome of the functioning of many of these 
different mechanisms in concert. Indeed, many host factors may impact the ultimate 
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expression of health effects imparted by a probiotic, including properties of baseline 
microbiota. Although few data exist, one study tracking probiotic persistence in the 
gut was linked to properties of the baseline microbiota. Persistence of B. longum 
subsp. longum AH1206 in the human gut was predicted by low abundance in the 
host of B. longum and low microbial carbohydrate utilization genes.32 No clinical 
endpoints were tracked in this study, but the property of long-term persistence may 
contribute to physiological benefits. However, results of many different clinical trials 
that do not include stratification of subjects by baseline microbiota suggest that 
probiotic function is not necessarily predicated on a specific microbiota baseline.33,34 
There may well be compositional patterns of microbiota that do not respond well to 
incoming probiotic strains, just as there are for certain drugs,35 but such profiles have 
not yet been fully defined.   
[H3] Modulation of cell-mediated and humoral immune functions. Some 
probiotics have been shown to increase phagocytosis or natural killer cell activity and 
interact directly with dendritic cells (reviewed in36) Some also demonstrate the ability 
to upregulate antibody secretion translating into improved defences against 
pathogens and augmenting vaccine responses.37-39 Probiotic strains can increase 
levels of anti-inflammatory cytokines such as tumour necrosis factor with implications 
for abating colon cancer and colitis.10,36 As discussed later, cell-surface architecture, 
such as fimbriae, capsule and surface structures expressed by certain probiotics is a 
mechanistic driver for several of these activities. 
[H3] Production of organic acids. Probiotic species belonging to the Lactobacillus 
and Bifidobacterium genera produce lactic and acetic acid as primary end-products 
of carbohydrate metabolism. These organic acids when produced in situ can lower 
luminal pH and discourage growth of pathogens as shown in various model 
systems.40-42 Lactobacillus and Bifidobacterium do not produce butyrate but through 
cross-feeding other commensal microbiota (for example, Faecalibacterium), levels of 
butyrate and other short-chain fatty acids in the gut can increase, potentially 
influencing many aspects of physiology, including the cardiometabolic phenotype.43 
This phenotype can be derived from increased production of butyrate, correlating 
with improved insulin response, or abnormalities in propionate linked to type 2 
diabetes.44 Based upon analyses of weight, lifestyle, metabolic measurements and 
short chain fatty acid (SCFA) levels, the risk of subjects developing cardiometabolic 
diseases can be calculated.45  
[H3] Interaction with gut microbiota. Probiotic strains can interact with the gut 
microbiota through competition for nutrients, antagonism, cross-feeding and support 
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of microbiota stability.46 Many probiotic strains are antagonistic toward other 
microbes, in part due to saccharolytic metabolism, which produces organic acids, but 
also by production of bacteriocins.47 These antimicrobial compounds can be active 
against pathogens at many sites including the human urinary tract and in the gut of 
humans or animals.48,49 Bifidobacteria produce acetate and can cross-feed other 
members of the gut microbiota (reviewed in50). Strains B. longum AH1206 and B. 
bifidum-ATCC15696 have been shown to persist in the infant gut,32,51 although in the 
latter case the concomitant decrease in pathogen abundance was not tested for a 
link to bacteriocin production. The ability of certain probiotic strains to improve 
eradication of Helicobacter pylori may involve some inhibition of the pathogen, but 
stronger evidence for probiotics in this context is for reducing side effects of 
antibiotics used in treatment.52 
[H3] Probiotic–host interactions. Interactions of probiotic strains with host tissues 
are mediated by cell surface macromolecules, including proteins (surface layer 
associated proteins, mucin binding proteins, pili, and LPxGT-binding proteins) and 
non-protein components (lipoteichoic acid, peptidoglycan, exopolysaccharides).53 
These structures have been shown to affect binding to intestinal and vaginal cells, 
mucin, and immune or dendritic cells resulting in increased transit times and 
improved barrier integrity (reviewed in53). An example of the different surface 
structures can be seen in the genome comparison of L. rhamnosus GG that uses pili 
to interact with the intestine and L. rhamnosus GR-1 with a unique cluster of 
exopolysaccharides to aid in vaginal activity.54    
[H3] Improvement of barrier function. Primarily through studies in cell lines, 
several probiotic Lactobacillus and Bifidobacterium strains have been shown to 
increase expression of tight junction proteins (reviewed in55). A study using human 
intestinal epithelial enteroids and colonoids showed that L. rhamnosus GG pre-
treatment countered damage to tight junction zonula occludens 1 (ZO-1) and 
occludin (OCLN) caused by interferon-gamma.56 Another way in which probiotic 
strains may improve barrier function is through upregulating expression of mucus 
secretion genes, thereby reducing pathogen binding to epithelial cells.57,58. Down-
regulating inflammation is also regarded as a factor that improves barrier function.53 
Of note, although some probiotic strains have the capacity to improve barrier 
function, this does not always occur in every cohort for reasons not yet fully 
understood.59  
[H3] Manufacture of small molecules with local and non-local effects. Small 
molecules produced by certain probiotic strains have been described with different 
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effects on the host and its microbiota.58 Perhaps one of the more intriguing findings is 
the production of neurochemicals such as oxytocin, gamma-amino butyric acid, 
serotonin, tryptamine, norepinephrine, dopamine and acetylcholine (reviewed in60, 
61,62) known to affect brain function. In a rat model of stress, L. helveticus NS8 
feeding resulted in lower plasma corticosterone and adrenocorticotropic hormone 
levels and restored hippocampal serotonin and norepinephrine.63 
[H3] Production of enzymes. Microbial enzymes such as β-galactosidase64 and bile 
salt hydrolase,65 which are produced and delivered by some probiotic strains, 
improve lactose digestion and blood lipid profiles in humans, respectively. In the case 
of Streptococcus thermophilus in yogurt, which facilitates lactose digestion, its 
predisposition to be permeabilized by bile when entering the small intestine promotes 
the delivery of microbial β-galactosidase to the small intestine to break down lactose 
into digestible glucose and galactose.64 This results in clinical benefit to individuals 
who are lactose intolerant. Indeed, the European Food Safety Authority considered 
evidence of this effect sufficient to authorize a health claim for S. thermophilus and L. 
bulgaricus as components of yogurt to alleviate symptoms of lactose maldigestion.66 
Admittedly, cause and effect evidence of mechanisms in human hosts 
remains to be gathered, but technological advancements in genome sequencing and 
microbiome analyses, and surgical advances that allow real-time sampling in vivo, 
should help acquire elucidating data over the next few years.  
 
[H1] Prebiotics 
If we are to understand how prebiotics work, and more importantly exploit them to 
manipulate the microbiota to propagate health, then we need to keep in mind that 
microbes live in complex functional ecosystems. Within these, bacteria have a 
multitude of roles, including the conversion of incoming dietary carbohydrates, 
proteins and some fats into metabolites that can have either positive or negative 
effects upon host health.67,68,69,70. Current prebiotics are predominantly 
carbohydrate-based, but other substances such as polyphenols and 
polyunsaturated fatty acids may exert prebiotic effects.6 An example of polyphenols 
is water-insoluble cocoa fraction, shown in a gut model to significantly increase 
bifidobacteria,  lactobacilli and butyrate production.71  
 Low molecular weight carbohydrates are very efficiently metabolised by 
microorganisms such as bifidobacteria, which possess a range of cell-associated and 
extracellular glycosidases and specific transport systems allowing them to rapidly 
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assimilate low molecular weight sugars.72,73 Other microbes, such as members of the 
Bacteroides genus are adept at breaking down high molecular weight 
polysaccharides.74,75 Some bacteria might be regarded as keystone, having the ability 
to initiate breakdown of particular substrates;76 for example, Ruminococcus spp. can 
facilitate resistant starch degradation.77 Liberated low molecular weight dextrins are 
then metabolized by the microbial community. The pathway from a polysaccharide to 
a SCFA is thus a complex and indirect network of metabolism. Acetate and lactate, 
the main metabolic end products of bifidobacteria and lactic acid bacteria, are utilised 
by other microorganisms to produce, for instance, propionate78 and butyrate.50,79 
Likely ecological networks involved in the metabolism of carbohydrates have been 
elucidated,74,80,81 although the extent to which they operate in the gut is not clear at 
the present time. 
 A further complication in studies of the ecosystem response to carbohydrates 
is that it is heavily influenced by the microorganisms that are already present. It has 
become clear that individual microbiomes that are Prevotella-dominant can ferment 
carbohydrates more rapidly than can Bacteroides-dominant microbiomes.82 
Furthermore, when these distinct faecal inocula, dominated by Prevotella or 
Bacteroides, were incubated with prebiotic fructo-oligosaccharides (FOS) or with two 
different arabinoxylans, the profile of SCFA produced was distinctly different and 
correlated with the microbiome.83 Cultures using Prevotella-dominant inocula 
produced significantly higher ratios of propionate to acetate and butyrate than the 
Bacteroides-dominant microbiotas. A similar influence of starting microbiome 
composition on carbohydrate fermentation has been seen using isomalto-
oligosaccharides as a carbon source in an in vitro batch fermentation model with 
human microbiota.84  
 Microbiome studies based on 16s rDNA sequencing have given rise to an 
increased awareness of the richness of the gut microbial ecosystem85 and, in some 
cases, to associations between certain microorganisms or microbiome profiles and 
disease states. These include IBD,86 type II diabetes mellitus,87-89 IBS90,91 and 
obesity.92,93. These profiles have frequently been termed “dysbioses”, although it is 
not currently possible to define such a state as ‘normobiosis’ or a ‘normal’ microbiota 
Such associations tend to be merely the starting point for investigation into the role of 
specific microorganisms in disease. Sequencing studies do not give us an 
understanding of the functional interactions between members of the gut microbiota 
and it is imperative that this functional ecology is studied in more detail. It is becoming 
clear that although there might be a huge diversity of individual taxa in the gut 
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microbiomes of individuals, there is a high level of functional redundancy, and specific 
ecological functions are provided by a range of bacteria across different 
individuals,94,95. 
 Given that we have an imperfect understanding of the functional ecology of 
the gut microbiota, uncovering the mechanisms of action of prebiotics presents a 
challenge. Despite this issue, we can postulate probable mechanisms by which a 
prebiotic can lead to health benefits. These pathways are presented in Figure 2 and 
discussed herein. All of these postulated mechanisms have support from research 
carried out through in vitro or animal models, although in many cases, establishing 
that they actually occur within human gut microbiota is difficult. 
[H3] Defence against pathogens. Although mechanistically challenging to establish 
in humans in vivo, pathogen defence can be investigated in vitro using model 
systems.96,97. As noted for probiotics, production of organic acids through prebiotic 
administration and propagation of beneficial bacteria will result in a reduction in 
luminal pH, inhibiting growth of pathogens. Establishment of a stable population of 
commensal microorganisms will reduce nutrient availability for invading 
microorganisms, inhibiting colonisation. In studies of elderly individuals, 10 weeks of 
daily galactooligosaccharide (GOS) intervention induced increases in immune 
function, notably enhanced phagocytic activity and activity of natural killer cells.98,99.  
[H3] Immune modulation. Although exact mechanisms are unclear, there is 
evidence that prebiotic intervention can reduce type 2 T helper responses and thus 
affect allergy. The most supportive data come from studies in infants. Galacto- and 
long chain fructo-oligosaccharides in infant formula administered in a double-blind, 
randomized, placebo-controlled trial of 259 infants, showed reduced incidence of 
atopic dermatitis, wheezing and urticaria to less than 50% of the incidence in non-
prebiotic formula fed infants.100,101 In a prospective, double blind, placebo-controlled 
fashion, not as yet replicated, healthy term infants at risk of atopy fed prebiotic-
supplemented hypoallergenic formula for 6 months had a greater than five-fold 
reduction in prevalence of allergies five years after feeding.102  
[H3] Increased mineral absorption. Most absorption of minerals takes place by 
active transport mechanisms in the small intestine,103 Scavenging calcium could make 
a substantial positive contribution to health. As already discussed, fermentation of 
prebiotics leads to production of SCFA, which reduces luminal pH. This drop in pH 
can increase calcium solubility, thereby providing a greater driving force for passive 
uptake. A problem with proving this is that many calcium salts in supplements and 
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food have pH-dependent solubility and limited availability, and depending on the 
starting pH, solubility of calcium can actually increase with higher pH.104 
 Studies have shown that consumption by young adolescents of a mixture of 
FOS and inulin105,106 or GOS107 can result in marked increases in absorption and 
calcium mineralised into bone. Such early intervention may reduce incidence of 
osteoporosis in later in life. This hypothesis is supported by animal model data108, but 
long-term studies in humans are lacking. 
[H3] Improved bowel function. Improvements in bowel function have often been 
ascribed to simple faecal bulking by consumption of dietary fibre. However, animal 
studies have shown that SCFAs produced by fermentation of prebiotics can regulate 
gut hormones that in turn modulate the local motor responses of the gut109,110. The 
humectant water binding capacity of prebiotic carbohydrates also has the effect of 
softening stools, making passage easier.111,112 
 There are surprisingly few studies on the effect of prebiotics on bowel 
function, although they have consistently led to improvements in stool consistency 
and defecation frequency in randomized trials113,114  
[H3] Metabolic effects. As discussed earlier, prebiotic intervention results in the 
elaboration of SCFAs that can act to improve barrier function in the gut and prebiotic 
intervention with GOS has shown improvements in barrier function in vivo.115 Impaired 
barrier function can allow translocation of inflammatory mediators such as bacterial 
lipopolysaccharide (LPS) from the gut into systemic circulation, which has been 
termed metabolic endotoxaemia116 and has been suggested to be a causative factor 
in diabetes and obesity according to evidence, albeit from studies in mice.117, 118. 
 Metabolic effects of prebiotics have been subject to several meta-
analyses119,120,121,122 and although the results among studies vary, the general 
consensus is that prebiotic intervention has a positive effect on glucose homeostasis, 
inflammation and blood lipid profile in humans. Although interventions with GOS123 
and inulin124 have shown improvements in inflammatory markers in individuals with 
obesity, these have been relatively short-term studies over a few months and the 
effect on metabolic health over a long period of consumption is yet to be established.  
 The hypothesis underlying much research on prebiotics and barrier function 
and inflammation is that fermentation products such as SCFA probably mediate the 
beneficial effects through mechanisms discussed above. However, it has been shown 
that, at least in vitro, GOS can directly stimulate the expression of tight junction 
proteins in intestinal epithelial cell lines and decrease trans-epithelial flux125,126. Given 
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that GOS is fermented in the gut, however, the extent to which such mechanisms act 
in vivo are unclear at present. 
 It is possible that the effect of inulin in improving glycaemic response could be 
due to direct inhibition of the intestinal isomaltase-sucrase enzyme complex, but so 
far the evidence is only from mouse studies127. Identification of direct mechanisms 
from metabolic mechanisms in humans is, however, extremely difficult. 
[H3] Effect on satiety. SCFAs produced by fermentation in the gut can interact with 
specific fatty acid receptors, FFAR2 and FFAR3 and regulate lipolysis and release of 
the incretin glucagon-like peptide-1.128,129  These receptors are found on many tissues 
and could be a key mechanistic link between prebiotic fermentation and systemic 
health benefits. SCFAs can regulate appetite via several mechanisms,130 with studies 
showing that the interaction between SCFA and colonic L-cells results in production 
of anorexigenic hormones such as PYY and GLP-1. Other examples are SCFAs 
surviving metabolism by colonic epithelial cells can reach the liver via the hepatic 
portal vein where propionate stimulates gluconeogenesis, acting as a satiety signal.131 
SCFAs entering the circulation could also interact with FFAR2 and FFAR3 located on 
adipose tissue, resulting in leptin stimulation. According to a study in mice, acetate, 
the principal SCFA formed by prebiotic fermentation, can cross the blood-brain barrier 
and enter the hypothalamus, promoting anorectic signals.132 
 
[H1] Translation to the clinic  
Box. Overcoming barriers to translation to the clinic 
 
 More high quality, adequately powered randomized, controlled trials that test 
well-defined probiotic (strain or strain combinations, dose, delivery matrix) and 
prebiotic interventions on substantive clinical outcomes. 
 Better tracking of safety data during the conduct of short and long term clinical 
trials   
 Improved availability of high quality, properly labelled, and effective commercial 
products133 
 Application by clinicians of available efficacy data in evidence-based manner. 
This comprises assessment of totality of data (positive and null) through unbiased 
systematic review processes for specific probiotic and prebiotic interventions.  
 Better understanding of characteristics of host (including diet, baseline 
microbiota, medications and disease) that improve response to probiotics or 
prebiotics 
 Clinicians need clarification about probiotic and prebiotic products: are they safe, 
who will benefit – how and to what extent, and can the product labels be trusted 
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Many clinical gastrointestinal indications could benefit from probiotic and prebiotic 
interventions. In the case of prebiotics, a link between the clinical benefit to 
microbiota function should be established. For probiotics, a clinical indication is 
needed. For both, robust product information is required133. 
There are clinical indications for use of certain probiotic strains supported by 
robust evidence. In paediatric and/or adult populations, evidence exists for 
necrotizing enterocolitis (NEC),134 antibiotic-associated diarrhea (AAD) and H. pylori 
infection135,136,137, defecation frequency138,139, infantile colic,140, mild to moderate 
ulcerative colitis,141 irritable bowel syndrome,142 treatment of acute diarrhea143 
prevention of C. difficile-associated diarrhea144 and neonatal sepsis.28 A recent meta-
analysis provided evidence that probiotic use has the potential to decrease antibiotic 
utilization in children.145 Some clinical guidelines have been issued for probiotic use 
in children.146,147 Systemic from the gut, evidence exists for reduction of incidence 
and duration of upper respiratory tract infections.147,149 No official recommendations 
have been made for adult uses of probiotics. Additional research clarifying the most 
effective strains and doses is needed for many clinical targets so far 
researched.150,151,152 Although many clinical indications are promising, data are still 
emerging for endpoints including brain, metabolic, and cardiovascular effects. 
 Generally, the strength of evidence for prebiotic interventions lags behind 
those for probiotics. Perhaps the strongest support for prebiotic use comes from 
prebiotic infant formulae. Such products are now routinely supplemented with 
mixtures of GOS and fructans153,154 and this blend of prebiotics in a 9:1 ratio reduced 
respiratory tract infections to levels found in breast-fed infants.155,156 101 There is less 
evidence that prebiotics can reduce infections in adults, although one placebo-
controlled, randomized, double blind study of 159 healthy volunteers, showed that 
GOS could reduce the incidence of diarrhea.157 
 Much of the research focus on prebiotics has been in the realm of functional 
food (improves well-being through benefit beyond its nutrient content) applications. 
The one example of a prebiotic food application recognized by European regulatory 
authorities is on improved bowel function in healthy adults resulting from consumption 
of 12g of chicory inulin per day.158,159 
 Prebiotic foods designed to increase satiety and reduce energy intake is a 
promising approach to augment compliance with weight loss diets. Oligofructose-
enriched inulin in overweight children has been shown to increase satiety, reduce 
energy intake as well as BMI and body fat mass over 16 weeks (body weight 
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decrease of 3.1%, percent body fat decrease of 2.4% compared with children given 
placebo (increase of 0.5%, increase of 0.05% respectively).160,161 Oligofructose 
ingested daily by 29 adults for 12 weeks in a granola bar formulation, reduced by 0·3 
(sd 1·2) kg lean mass and waist circumference by -2·2 (sd 3·6) cm, with a 
concomitant intake and increase satiety in adults over a 12-week intervention.162 
However, not all studies have suggested benefits. One study of 97 overweight or 
obese children given oligofructose for 12 weeks did not show a statistically significant 
change in BMI-for-age z-score versus placebo.163 This study did not measure the 
effect of the prebiotic on the gut microbiota and its function, which would have 
provided mechanistic insight to better understand the null study results and enabled 
better design of future interventions.  
 The replacement of glycaemic carbohydrates in food products with non-
glycaemic carbohydrates to reduce post-prandial glycaemic responses has already 
received a positive EFSA opinion.164 Prebiotic carbohydrates might be expected to 
bring additional benefits in terms of increasing satiety in such a replacement strategy. 
Promising results were observed from a double-blind, randomized, controlled cross-
over trial of 40-42 healthy adults who consumed a yogurt drink containing 
oligofructose. The intervention improved postprandial glucose responses.165 
 There is now some evidence that the stool microbiota profiles of patients with 
inflammatory conditions, such as inflammatory bowel disease, differs from those who 
are heathy,166 but it is not clear at the present time why. It is unclear whether these 
differences are caused by the underlying medical condition, are a consequence of the 
disease pathology, or due to confounding factors such as medications or altered 
dietary habits. Probiotic or prebiotic interventions hold promise to achieve disease or 
symptom mitigation through microbiota modulation. An understanding of the 
microbiome composition and function in the donor and recipient will help us 
understand the extent to which clinical success depends on these factors.167 Indeed, 
some clinical trials have noted the importance of baseline microbiota composition 
among responders.168,169,170  Microbiota patterns can be influenced by lifestyle, living 
conditions, diet, medications and stool consistency, among other transient variables. 
Advanced age is also thought to be a factor, but one study of Chinese subjects has 
shown that healthy centenarians have similar microbiota to healthy young people,171 
suggesting that factors other than age are more important drivers of microbiota 
composition. Furthermore, research methodologies and data management may lead 
to spurious interpretations of microbiota assessments, which has the potential to 
mislead.172 Although clinical benefits have been observed with probiotic and prebiotic 
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interventions, the onus is on researchers to clarify the role of the microbiome in these 
successes to optimize short and long-term outcomes.173,174,175,176,177.  
Careful phenotypic and genotypic descriptions of study subjects may also be 
important to clinical trial success targeting the microbiome. Host genetic studies may 
help, for example, in the microbiome-mediated disease of IBD, where 163 loci were 
identified to meet genome-wide significance thresholds.178 However, since the 
majority of cases of IBD are not the result of a single host gene defect,179 
complicating the development of clinical interventions based on host genetics. 
Another complication is that identified genes constitute risk factors, not causal 
determinants, for a disease, and therefore clinical strategies based on host genomics 
have not been forthcoming.  
IBD comprises two main forms, Crohn’s disease and ulcerative colitis. In 
Crohn’s disease, there seems to be distinct molecular subclasses of genomic 
associations, further complicating development of effective strategies.180 This may in 
part explain why probiotic strains have mostly failed to be effective in improving the 
management of Crohn’s disease.181,182 The reason why mild to moderate ulcerative 
colitis has been somewhat improved by probiotic intervention183 but Crohn’s is not 
known. The future success of microbiota manipulation to mitigate serious 
inflammatory conditions will require an understanding of the interactions between the 
microbiome and the human genetic risk factors and will necessitate moving beyond 
microbial genomic sequencing to transcriptomic, metabolomic and proteomic 
investigations. 
The promise of treating or curing disease with microbiota manipulation 
continues to be explored using probiotic species different from those traditionally 
employed184. Many probiotics in current use are from the genera Lactobacillus and 
Bifidobacterium. Although many of them were derived from the faeces or intestinal 
mucosa of healthy human subjects, researchers today are considering the utility of 
many newly explored human resident microbes, such as Akkermansia, Eubacterium, 
Propionibacterium, Faecalibacterium and Roseburia.  This will require going beyond 
laboratory animal experiments that proliferate in the literature.185,62  
Faecal microbial transplantation (FMT), which has been a reasonably 
successful treatment for recurrent Clostridium difficile infection,186,187,188 is being met 
with mixed success in the treatment of other conditions189-191. Although FMT is not a 
probiotic application since it is not suitably defined microbiologically to meet the 
probiotic definition,2 the approach is based on the concept that microbes derived 
from healthy donor feces can restore proper function to a dysbiotic microbial 
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ecosystem.  It is noteworthy that there have only been a few blinded, randomized 
controlled trials (RCTs) on FMT for treatment of recurring C. difficile, and these have 
been relatively small studies and we have little information on the long-term changes 
that such a broad, poorly defined and non-specific treatment might have on 
individuals. A well-defined reproducible probiotic intervention is more suitable for 
rigorous research investigation and could be safer long-term than FMT, as suggested 
by several researchers attempting to assemble a defined consortium of microbes for 
such purposes 192. Whether these defined consortia, typically comprising many 
human commensal microbial species, can reach the same levels of cure as FMT 
remains to be seen.  
The potential impact of gut microbiota manipulation on clinical medicine is 
promising. However, in the excitement over potential, stakeholders often forget that 
association does not mean causation. For example, blinded reviews of 34 
oesophageal biopsy samples found that these microbiomes could be classified into 2 
types. Type I was dominated by the genus Streptococcus and was phenotypically 
normal. But Type II, demonstrating a greater proportion of Gram-negative anaerobes 
and/or microaerophiles, correlated with oesophagitis and Barrett oesophagus.150 Like 
many other microbiome findings, this does not prove causation and there are 
numerous potential reasons why these associations might exist, including diet, drugs, 
and lifestyle. One hypothesis might be that administering a safe, select 
Streptococcus could reduce oesophagitis and Barrett's oesophagus, but this has not 
been tested. Microbiome differences do not necessarily mean that microbiota 
modification will lead to improved health. 
 
[H1] The future  
The gut microbiota might be central to the cause of many disorders and its 
modulation could hold the key to new effective therapies. So, what are the roles of 
probiotics and prebiotics? In a general sense, both interventions serve to increase 
the community of beneficial microorganisms and products of their growth and 
metabolism in the host. In this context, effects relayed might exert influences 
systemically, such as in the cardiovascular system, or to the urogenital tract, skin and 
brain.193  
The field is poised for conceptual advances. Target microbes will expand 
beyond the typical Bifidobacterium spp. and Lactobacillus spp. (as mentioned above) 
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to include other genera and maybe more yeast species.194-197 These microorganisms 
might be new probiotic candidates or further targets for prebiotic utilization.  
Improved precision, accuracy, and repeatability of measures of microbial 
composition, which lead to genuine and not misleading interpretations, are needed in 
this field.172 Improved assessments will lead to an expanded range of probiotic and 
prebiotic products. For example, propionate and butyrate are both considered to be 
beneficial gut microbial metabolites, but neither is produced by bifidobacteria or 
lactobacilli.198,199 Therefore, an opportunity exists to define microbes with metabolic 
capabilities beyond those afforded by traditional probiotics.  
Another development could be anti-adhesive molecules and carbohydrates 
that attenuate microbial virulence. These factors would be adjuncts to current 
prebiotic approaches in that they are not selectively utilized substrates.  
To have robust proof that gut microbiome alterations can reduce disease 
incidence or mitigate disease, more well-designed RCTs are needed. By randomly 
assigning individuals to intervention groups, most biases are reduced and the 
chances of useful results are improved. Due to the easy availability and relatively 
cheap cost of high-throughput sequencing technology, microbiota analysis is 
becoming widespread and differences among disease states increasingly well 
publicized. The expertise and databases required for metabolomic analysis is also on 
an upward trend. This will be vital to optimise clinical translation, as a much greater 
awareness of the functional ecology of the gut is needed together with improved 
clarity of how this ecosystem influences systemic health. Microbiota and host 
transcriptomic studies are also important, but they are expensive, time-consuming 
and require substantial bioinformatic support. Ultimately, the application of probiotic 
and prebiotic regimens has the potential to improve human health and contribute 
greatly to how patients are managed and/or disease risk is reduced.  
[H1] Conclusions 
Although certain commonalities allow us to group substances under the ‘probiotic’ or 
‘prebiotic’ umbrellas, benefits to human health are tied to specific products, not the 
categories en masse. To the extent that a clinical outcome is associated with a 
specific mechanism of action, then it could be hypothesized that a similar strain or 
prebiotic expressing that mechanism might also be beneficial. However, it is 
important not to overgeneralize conclusions about specific entities. In general, when 
an intervention is effective or ineffective, it must be recognized that those results are 
tied to specific formulations, doses, clinical endpoints and target populations. It is 
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incumbent upon responsible scientists to consider the totality of available information 
on specific interventions as a basis of overall conclusions on effectiveness. 
Furthermore, clinicians should scrutinize both positive and null studies for bias, as 
only in eliminating bias in research will we move the field toward truth, thereby 
realising the potential of probiotics and prebiotics. 
The body of research suggests that these interventions can not only improve 
symptomology, but have a meaningful effect on reducing pathology and even saving 
lives. The prevention of sepsis and NEC in infants provides compelling examples. 
These findings demonstrate effective translation of human microbiome research. 
Such clinical impact has changed practice in many healthcare environments. Yet 
many constituencies have yet to embrace the concept through critically considering 
the strengths and weaknesses of existing data.   
In developing countries, probiotics widely available in developed countries are 
either not accessible or affordable to most people. However, a program has 
introduced inexpensive sachets containing a probiotic L. rhamnosus (GR-1 or Yoba 
2012) plus S. thermophilus C106 that allows locals to produce different forms of 
fermented foods (yoghurt, millet, cereals, juices) that not only influence health but 
also empower poverty-stricken communities to improve social well-being.4 With over 
260,000 consumers being reached each week in East Africa, the potential is 
enormous to use these beneficial microbes and local food sources to impact 
communities (manuscript submitted).  
Diseases and poor health often result from the interplay of microbiological 
and biological ecosystems along with societal issues including pollution, food 
shortages and poor medical care.200,201 We encourage more research and 
translational efforts on probiotics and prebiotics to serve the people of developing 
countries, who might stand to benefit most from these interventions.  
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The gut microbiota has been implicated in a range of diseases with microbiota 
manipulation suggested as a possible therapeutic approach. This Review describes 
current understanding of probiotics and prebiotics as a means to manage the 
microbiota to improve host health, including mechanisms of actions and potential for 
clinical use. 
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Figure 1. Probiotic mechanisms of action. Diverse mechanisms are likely to drive 
probiotic benefits to host health. In some cases, such as production of antimicrobial 
products and cross-feeding other resident microbes, these mechanisms are driven 
directly by interactions with the resident microbiota. In other cases, such as direct 
interaction with immune cells, their effects might be directly via interaction with host 
cells. Overall, clinical benefits delivered by probiotics could result from the combined 
action of several mechanisms.  
GABA, gamma amino butyric acid.  
 
Figure 2. Identified mechanisms of action of prebiotics  
The premise is that prebiotics enter the gut and are selectively utilized. This step 
increases bacterial growth and functionality of specific genera or species. As a result 
of either or both of these effects, health benefits can then accrue. Fecal bulking and 
improved bowel habits occurs due to microbial growth. Immune regulation can be 
influenced by increased biomass and cell wall components of the bacteria. Metabolic 
products include organic acids, which lowers intestinal pH and have concomitant 
effects upon microbial pathogens and mineral absorption. Metabolic products can also 
influence epithelial integrity and hormonal regulation. Bacteria that respond to prebiotic 
intake can influence the microbiota composition through elaboration of antimicrobial 
agents (e.g. peptides) and competitive interactions, possibly reducing infections and 
bacteria containing LPS. 
GLP, glucagon like peptide; IL – interleukin; LPS,  lipopolysaccharide; PYY, peptide 
YY; TGF, transforming growth factor; Th1, type 1 T-helper cell, type 1; Th2, type 2-T 
helper cell; Tr, regulatory T cell.  
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